Please assess the completion status of the following clinical trial:

Trial Title: Oseltamivir Randomised Controlled Efficacy Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Persons at least one year old residing in randomly selected households with at least one major illness sign, or if absent at least two minor illness signs who are rapid test positive for either influenza A or influenza B.~Exclusion Criteria:~* Persons with a history of non-febrile convulsions or~* Persons who are taking anticonvulsive agents, or~* Persons who have a nonrespiratory comorbid condition requiring immediate medical intervention, or~* Persons who are pregnant.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Oseltamivir for 5 days for patients with illness duration \< 48 hours
- 2 (Type: PLACEBO_COMPARATOR): Placebo for 5 days for patients with illness duration \< 48 hours
- 3 (Type: EXPERIMENTAL): Oseltamivir for 5 days for patients with illness duration ≥ 48 hours
- 4 (Type: PLACEBO_COMPARATOR): Placebo for 5 days for patients with illness duration ≥ 48 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).